Market Access News | pharmaphorum

News

Can Keytruda finally break into early head and neck cancer?

The FDA is set to decide on MSD's Keytruda as perioperative treatment of locally advanced head and neck squamous cell carcinoma in June.

News

Lilly launches discounted high-strength Zepbound vials in US

Eli Lilly's drive to provide as many treatment options as possible for its obesity drug Zepbound has continued with the launch of new high-dose vials.

News

FDA clears first therapy for rare disease CTX from Mirum

Mirum Pharma's Ctexli has become the first FDA-approved therapy for ultra-rare disease cerebrotendinous xanthomatosis (CTX).

News

Pfizer drops Beqvez, leaving its gene therapy cupboard bare

Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.

News

Compounders cast adrift after semaglutide shortage ends

The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.

News

NICE backs consolidation use of Blincyto in leukaemia

NICE backs NHS use of Amgen's Blincyto for the consolidation phase of treatment for some patients with acute lymphoblastic leukaemia.

Can Keytruda finally break into early head and neck cancer?

Lilly launches discounted high-strength Zepbound vials in US

FDA clears first therapy for rare disease CTX from Mirum

Pfizer drops Beqvez, leaving its gene therapy cupboard bare

Compounders cast adrift after semaglutide shortage ends

NICE backs consolidation use of Blincyto in leukaemia

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks